---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-26-000028"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:58:36.906731+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axogen Q4 revenue $59.9M (+21%); FY2025 $225.2M; guides 2026 growth >=18%

## Summary
- Q4 revenue $59.9M (+21.3% YoY); net loss $13.2M ($0.28/sh); adjusted net income $3.5M ($0.07/sh).
- FY2025 revenue $225.2M (+20.2% YoY); adjusted net income $14.4M ($0.29/sh); adjusted EBITDA $27.9M.
- FDA approved Avance BLA on Dec 3, 2025; CMS new Level 3 code raises Avance facility reimbursement 40% to $8,965.
- Closed upsized public offering of 4.6M shares for $133.3M net; $69.7M used to repay Oberland loan facility.
- 2026 guidance: revenue at least $265.7M (+18% YoY); gross margin 74%-76%; expects positive free cash flow.

## SEC filing metadata
- accession: 0000805928-26-000028
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592826000028/0000805928-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592826000028/axgn-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-26-000028
- JSON: https://secwatch.observer/filing/0000805928-26-000028.json
- Plain text: https://secwatch.observer/filing/0000805928-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.